Results 1 to 10 of about 420,874 (246)

Hepatitis B Vaccines. [PDF]

J Infect Dis, 2021
Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality.
Pattyn J, Hendrickx G, Vorsters A, Van Damme P.   +3 more
europepmc   +6 more sources

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab. [PDF]

Crohns Colitis 360, 2020
Background Patients with inflammatory bowel disease (IBD) have an elevated risk for infection which is further increased by immunosuppressive medications.
Harrington JE, Hamilton RE, Ganley-Leal L, Farraye FA, Wasan SK.   +4 more
europepmc   +2 more sources

Hepatitis B vaccines.

Journal of Hepatology, 2003
Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
D. Shouval
semanticscholar   +3 more sources

Vaccination Strategies Against Hepatic Diseases: A Scoping Review [PDF]

Vaccines
Background/Objectives: Viral hepatitis remains a significant global cause of chronic liver disease, highlighting the importance of effective vaccination strategies. This review assesses recent evidence on vaccine safety and effectiveness.
Zahra Beyzaei, Bita Geramizadeh, Sara Karimzadeh, Ralf Weiskirchen   +3 more
doaj   +2 more sources

Booster Vaccination Against Invasive Pneumococcal Disease and Hepatitis B in Previously Vaccinated Solid Organ Transplant Recipients Without Seroprotection [PDF]

Vaccines
Background: Despite pre-transplantation vaccination against invasive pneumococcal disease (IPD) and hepatitis B virus (HBV), most solid organ transplant (SOT) recipients are without post-transplantation seroprotection against IPD and HBV.
Julie Sejerøe-Olsen, Moises Alberto Suarez-Zdunek, Thomas Helbo, Lise Bank Hornung, Charlotte Sværke Jørgensen, Kasper Rossing, Michael Perch, Allan Rasmussen, Sebastian Rask Hamm, Susanne Dam Nielsen   +9 more
doaj   +2 more sources

HBV Vaccines: Advances and Development

Vaccines, 2023
Hepatitis B virus (HBV) infection is a global public health problem that is closely related to liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic HBV infection, liver cirrhosis, and HCC has significantly decreased as ...
Faisal Mahmood, Ruixian Xu, Maher Un Nisa Awan, Yuzhu Song, Qinqin Han, Xueshan Xia, Jia Wei, Jun Xu, Juan Peng, Jinyang Zhang   +9 more
doaj   +1 more source

Prevalence of protective antibody levels against hepatitis B infection among healthcare workers in a tertiary care hospital in India

Asian Journal of Medical Sciences, 2023
Background: Hepatitis B virus (HBV) infection affects more than 2 billion individuals globally HBV. The chance of dying from liver cirrhosis, acute fulminant liver disease, or hepatocellular carcinoma (HCC) is present in 240 million of these chronic HBV ...
Ramesh Thanikachalam , Sathyan Elangovan , Jercy Grace   +2 more
doaj   +1 more source

Neonatal hepatitis B vaccination: Reevaluating timing and adjuvants for enhanced safety and effectiveness

Pediatric Discovery, 2023
Our aim is an achievement of a 100 percent vaccination rate without toxic vaccine effects. We did a comprehensive literature review on aluminum neurotoxicity and early neonatal hepatitis B vaccination.
Aleksandar Cirovic, Ana Cirovic, Ana Ivanovski, Petar Ivanovski   +3 more
doaj   +1 more source

EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA

Hematology, Transfusion and Cell Therapy, 2021
Objective: Our study aims to evaluate the patients’ immunity regarding childhood vaccination after leukemia treatment and determine the vaccines that require additional doses. Methodology: Sixty-six patients who were followed up with the diagnosis of ALL
Elif KILIC KONTE, Ayca KOCA YOZGAT, Aysun KARA UZUN, Hüsniye Nese YARALI, Bahar CUHACI CAKIR   +4 more
doaj   +1 more source

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]

, 2021
Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G, Frelin, L, Jagya, N, Johansson, M, Maravelia, P, Meuleman, Philip, Ni, Y, Pasetto, A, Pater, L, Pérez, NC, Sällberg, M, Urban, S, Verch, G, Verhoye, Lieven   +13 more
core   +1 more source